Main Article Content

Dr Syed Mehmood Haider Abidi
Dr Syeda Fizza Tahir Abidi
Dr Gori
Dr Komal Devi
Dr Kartaar Saahil
Dr Kapeel Kumar


Atherosclerotic Cardiovascular Disease (ASCVD), Dyslipidemia, hyperlipidemia, Cholesterol


Aim/Objective: To examine the effect of lipid-lowering therapy on reducing the risk of atherosclerotic cardiovascular diseases(ASCVD) in diabetics. 

Methodology: A longitudinal cohort-study was conducted at Liaquat National Hospital & Medical College, Pakistan in the duration from July, 2023 to December, 2023. Participants included individuals aged 18 to 70 with confirmed diabetes mellitus (DM). Exclusion criteria encompassed documented cardiovascular diseases, pregnancy, significant chronic conditions other than diabetes, lipid-lowering medication use, and smoking. Fasting lipid profile parameters were obtained at the start. Statin therapy was administered to participants with dyslipidemia/hyperlipidemia. Every six months, follow-up examinations were undertaken to track the occurrence of ASCVD.


Results: The study enrolled 100 participants, with 56.45± 10.59 years of mean age and diabetes period with a mean of 6.33± 1.75 years. Nineteen patients developed ASCVD during the study period. Initial lipid profiles showed mean LDL cholesterol of 112.75 ± 8.81mg/dL, HDL cholesterol of 42.89 ± 7.97mg/dL, and triglycerides of 146.81 ± 21.32mg/dL. Correlation scrutinizes revealed weak associations between lipid parameters and ASCVD after six months of statin therapy. 

Conclusion: Pakistani patients with type 2 diabetes often exhibit dyslipidemia predisposing them to ASCVD. Despite the potential benefits of statin therapy, its underutilization underscores the need for enhanced treatment adherence to mitigate cardiovascular complications. 

Abstract 118 | PDF Downloads 36


1. Gonzalez-Jaramillo N, Wilhelm M, Arango-Rivas AM, Gonzalez-Jaramillo V, Mesa-Vieira C, Minder B, et al. Systematic review of physical activity trajectories and mortality in patients with coronary artery disease. Journal of the American College of Cardiology.
2. Rosenzweig JL, Bakris GL, Berglund LF, Hivert M-F, Horton ES, Kalyani RR, et al. Primary prevention of ASCVD and DM2 in patients at metabolic risk: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.
3. Khalid MR, Lakho MA, Zubair M, Bhutto A, Abbas S, Yousif A. Correlation of lipid profile in diabetes patients: The potential for risk reducing of atherosclerotic cardiovascular disease.
4. Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology.
5. Federation I. IDF Diabetes Atlas, 9th edn.
6. Amelia R, Sari Wahyuni A, Yunanda Y, Wijaya H. Atherosclerotic Cardiovascular Disease in Diabetes Patients. Current Diabetes Reviews.
7. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease: Analysis of data from the World Health Organization and coronary artery disease risk factors From NCD Risk Factor Collaboration.
8. Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, et al. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors.
9. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. Journal of atherosclerosis and thrombosis.
10. Butool I, Nazir S, Afridi M, Shah SM. Evaluation and assessment of prescribing patterns in elderly patients using two explicit criteria based screening tools:(The PRISCUS list and STOPP/START criteria). Pakistan journal of medical sciences.
11. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Current cardiology reports.
12. Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment.
13. Committee ADAPP, Committee: ADAPP. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes care.
14. Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/ eicosapentaenoic acid. Pharmacology & therapeutics.
15. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Current diabetes reports.
16. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert review of clinical pharmacology. 2018.

Most read articles by the same author(s)